These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 26681898)

  • 1. A Clinical Reminder About The Safe Use of Insulin Vials.
    Grissinger M
    P T; 2015 Dec; 40(12):788-90. PubMed ID: 26681898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of commercially manufactured and compounded protamine zinc insulin.
    Scott-Moncrieff JC; Moore GE; Coe J; Lynn RC; Gwin W; Petzold R
    J Am Vet Med Assoc; 2012 Mar; 240(5):600-5. PubMed ID: 22332631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Inpatient Glycemic Control with Insulin Vials Versus Insulin Pens in General Medicine Patients.
    Horne J; Bond R; Sarangarm P
    Hosp Pharm; 2015 Jun; 50(6):514-21. PubMed ID: 26405343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic impact of converting from 10-mL insulin vials to 3-mL vials and pens in a hospital setting.
    Edmondson G; Criswell J; Krueger L; Eby EL
    Am J Health Syst Pharm; 2014 Sep; 71(17):1485-9. PubMed ID: 25147173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of vials and prefilled pens of a rapid-acting insulin analog on pharmacy budgets in a long-term care setting.
    Eby EL; Smolen LJ; Pitts AC; Krueger LA; Andrews JS
    Consult Pharm; 2014 Dec; 29(12):813-22. PubMed ID: 25521657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
    Eby EL; Boye KS; Lage MJ
    J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply Chain.
    Carter AW; Heinemann L
    J Diabetes Sci Technol; 2018 Jul; 12(4):839-841. PubMed ID: 29268624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coverage of insulin delivery devices and basal insulin analogs by US managed care organizations.
    Kimball ES; Aagren M
    J Med Econ; 2011; 14(6):720-8. PubMed ID: 21899485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is insulin diluted when stored in water?
    Plager P; Nurie K; Omann T; Moran A; Piloya T; Bahendeka S; Sunni M
    Pediatr Diabetes; 2017 May; 18(3):237-240. PubMed ID: 26826013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin pens vs. vials and syringes: differences in clinical and economic outcomes.
    Bastian MD; Wolters NE; Bright DR
    Consult Pharm; 2011 Jun; 26(6):426-9. PubMed ID: 21628141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flocculation and loss of potency of human NPH insulin.
    Benson EA; Benson JW; Fredlund PN; Mecklenburg RS; Metz R
    Diabetes Care; 1988; 11(7):563-6. PubMed ID: 3203573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demonstration of insulin transformation products in insulin vials by high-performance liquid chromatography.
    Gregory R; Edwards S; Yateman NA
    Diabetes Care; 1991 Jan; 14(1):42-8. PubMed ID: 1991434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact analysis of insulin therapies and associated delivery systems.
    Lee LJ; Smolen LJ; Klein TM; Foster SA; Whiteman D; Jorgenson JA; Hultgren S
    Am J Health Syst Pharm; 2012 Jun; 69(11):958-65. PubMed ID: 22610028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents.
    Kadiri A; Chraibi A; Marouan F; Ababou MR; el Guermai N; Wadjinny A; Kerfati A; Douiri M; Bensouda JD; Belkhadir J; Arvanitis Y
    Diabetes Res Clin Pract; 1998 Jul; 41(1):15-23. PubMed ID: 9768368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence.
    Asche CV; Shane-McWhorter L; Raparla S
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S101-8. PubMed ID: 20515297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic outcomes with the conversion of insulin delivery methods in hospitals.
    Kelton KA; Perk S; Loveland S; Perez-Nieves M; Fu H; Peng X
    J Med Econ; 2017 May; 20(5):533-540. PubMed ID: 28133990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes.
    Lucidi P; Porcellati F; Marinelli Andreoli A; Candeloro P; Cioli P; Bolli GB; Fanelli CG
    Diabetes Metab; 2018 Sep; 44(4):368-372. PubMed ID: 28599764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the maintenance of cleanliness of insulin vials used by patients: a model study on handling of vials].
    Watanabe K; Kudo S; Sato S; Tsushima R
    Kango Tenbo; 1987 Sep; 12(10):995-1001. PubMed ID: 3316856
    [No Abstract]   [Full Text] [Related]  

  • 19. Medication errors associated with transition from insulin pens to insulin vials.
    Trimble AN; Bishop B; Rampe N
    Am J Health Syst Pharm; 2017 Jan; 74(2):70-75. PubMed ID: 28069680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of insulin loss in treatment of diabetics using the classical syringe or the insulin pen (Novopen II)].
    Krahulec B; Strbová L; Seböková E; Cárský J; Klimes I
    Vnitr Lek; 1996 Sep; 42(9):640-5. PubMed ID: 8984774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.